Nonalcoholic Fatty Liver Disease

descriptionPublicationkeyboard_double_arrow_right Article 01 May 2016 English Publisher:North Carolina Institute of MedicineJournal:North Carolina Medical Journal, volume 77, pages 216-219 (issn: 0029-2559,

Copyright policy )

Authors: Tyler, Thrasher; Manal F, Abdelmalek;

doi: 10.18043/ncm.77.3.216

pmid: 27154894

Nonalcoholic Fatty Liver Disease

- Summary
- Subjects
- Metrics

Abstract

Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, is the leading cause of chronic liver disease. Treatments target lifestyle modification and improvement of underlying risk factors. Noninvasive biomarkers for diagnosis and staging of NAFLD and safe, cost-effective treatments for patients with nonalcoholic steatohepatitis (NASH) and/or NASH-related cirrhosis are currently under investigation.

Related Organizations

Duke University
United States

Keywords

Non-alcoholic Fatty Liver Disease, Humans

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	5
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average